Apatinib Combined With SOX Regimen in Conversion Treatment of Advanced Gastric Cancer: A Case Series and Literature Review

Apatinib Combined With SOX Regimen in Conversion Treatment of Advanced Gastric Cancer: A Case Series and Literature Review

Gastric cancer is a common digestive tract tumor and the second most prevalent cancer. The prognosis of advanced gastric cancer is poor. Conversion therapy can reduce tumor burden, downgrade tumor, and increase the possibility of complete resection, thus prolonging the survival time of patients with...

Full description

Bibliographic Details
Main Authors:	Dingyi Jiang, Yunyun Xu, Yunwang Chen, Jiahong Jiang, Mingxing Wang, Min Yang, Zheling Chen, Liu Yang
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2020-07-01
Series:	Frontiers in Pharmacology
Subjects:	apatinib gastric cancer conversion therapy case review
Online Access:	https://www.frontiersin.org/article/10.3389/fphar.2020.01027/full

Similar Items

Apatinib combined with SOX regimen for conversion therapy in advanced gastric cancer patients: a retrospective cohort study
by: Ya-Ya Deng, et al.
Published: (2023-04-01)

Short-term survival and safety of apatinib combined with oxaliplatin and S-1 in the conversion therapy of unresectable gastric cancer
by: Zaisheng Ye, et al.
Published: (2021-06-01)

Apatinib enhances chemosensitivity of gastric cancer to paclitaxel and 5-fluorouracil
by: Xu Z, et al.
Published: (2019-05-01)

Efficacy of Conversion Surgery Following Apatinib Plus Paclitaxel/S1 for Advanced Gastric Cancer With Unresectable Factors: A Multicenter, Single-Arm, Phase II Trial
by: Zhiyuan Xu, et al.
Published: (2021-03-01)

Adding of apatinib and camrelizumab to overcome de novo trastuzumab resistance of HER2-positive gastric cancer: A case report and literature review
by: Huifang Lv, et al.
Published: (2023-01-01)

Effectiveness and safety of low‐dose apatinib in advanced gastric cancer: A real‐world study
by: Yingying Du, et al.
Published: (2020-07-01)

Efficacy and safety of apatinib for the treatment of AFP-producing gastric cancer
by: Ningning Li, et al.
Published: (2021-02-01)

YY1: a key regulator inhibits gastric cancer ferroptosis and mediating apatinib-resistance
by: Zi-Han Geng, et al.
Published: (2024-02-01)

Multiple-dose up-titration study to evaluate the pharmacokinetics, safety and antitumor activity of apatinib in advanced gastric adenocarcinoma
by: Yonggang Wang, et al.
Published: (2022-10-01)

Expression of p53 as a biomarker in determining response to apatinib for advanced gastric cancer
by: Zhiyuan Qiu, et al.
Published: (2023-08-01)

Apatinib Suppresses Gastric Cancer Stem Cells Properties by Inhibiting the Sonic Hedgehog Pathway
by: Wanshuang Cao, et al.
Published: (2021-07-01)

Genome-wide CRISPR screen identifies ESPL1 limits the response of gastric cancer cells to apatinib
by: Bei Zhang, et al.
Published: (2024-02-01)

Integration of pharmacoproteomic and computational approaches reveals the cellular signal transduction pathways affected by apatinib in gastric cancer cell lines
by: Yosui Nojima, et al.
Published: (2023-01-01)

Efficacy and safety of apatinib combined with chemotherapy for the treatment of advanced gastric cancer in the Chinese population: a systematic review and meta-analysis
by: Cheng HG, et al.
Published: (2018-07-01)

Efficacy of the low dose apatinib plus deep hyperthermia as third-line or later treatment in HER-2 negative advanced gastric cancer
by: Guohu Han, et al.
Published: (2023-07-01)

Apatinib combined with PD-1 antibody for third-line or later treatment of advanced gastric cancer
by: Qingli Cui, et al.
Published: (2022-10-01)

Neoadjuvant apatinib combined with oxaliplatin and capecitabine in patients with locally advanced adenocarcinoma of stomach or gastroesophageal junction: a single-arm, open-label, phase 2 trial
by: Zhaoqing Tang, et al.
Published: (2022-04-01)

Case report: Long-term partial response of apatinib plus paclitaxel as second-line therapy in a patient with metastatic gastric cancer
by: Shengya Fu, et al.
Published: (2022-08-01)

Sintilimab Plus Apatinib and Chemotherapy as Second‑/Third-Line treatment for Advanced Gastric or Gastroesophageal Junction Adenocarcinoma: a prospective, Single-Arm, phase II trial
by: Le Zhang, et al.
Published: (2023-03-01)

Resection of unresectable hepatocellular carcinoma after conversion therapy with apatinib and camrelizumab: a case report and literature review
by: Xin-Liang Liu, et al.
Published: (2024-03-01)

Anorexia, Hypertension, Pneumothorax, and Hypothyroidism: Potential Signs of Improved Clinical Outcome Following Apatinib in Advanced Osteosarcoma
by: Xie L, et al.
Published: (2020-01-01)

Progress of Apatinib in Treatment of Non-small Cell Lung Cancer
by: LIANG Lijun, et al.
Published: (2018-11-01)

Experimental study of the vascular normalization window for tumors treated with apatinib and the efficacy of sequential chemotherapy with apatinib in lung cancer‐bearing mice and patients
by: Mingtao Liu, et al.
Published: (2020-04-01)

Research on the Mechanism and Prevention of Hypertension Caused by Apatinib Through the RhoA/ROCK Signaling Pathway in a Mouse Model of Gastric Cancer
by: Wenjuan Wang, et al.
Published: (2022-06-01)

Corrigendum: Research on the mechanism and prevention of hypertension caused by apatinib through the RhoA/ROCK signaling pathway in a mouse model of gastric cancer
by: Wenjuan Wang, et al.
Published: (2022-10-01)

A real-world study of the effectiveness and safety of apatinib-based regimens in metastatic triple-negative breast cancer
by: Weiwei Huang, et al.
Published: (2024-01-01)

Apatinib treatment for KIT- and KDR-amplified angiosarcoma: a case report
by: Lishu Yang, et al.
Published: (2018-05-01)

Clinical observation of apatinib in the treatment of metastatic colorectal cancer
by: CHEN Zhu, LIU Yan, GAO Li-hua, CHEN Bu-you, TANG Ai-hua, LIU Jun
Published: (2021-12-01)

Complete remission of alpha-fetoprotein-producing gastric cancer by combined tislelizumab-apatinib treatment of a patient with proficient mismatch repair: a case report
by: Jinyu Xiang, et al.
Published: (2022-09-01)

Efficacy and safety of apatinib in the treatment of osteosarcoma: a single-arm meta-analysis among Chinese patients
by: Hui Yao, et al.
Published: (2021-04-01)

Evaluation of second-line apatinib plus irinotecan as a treatment for advanced gastric adenocarcinoma or gastroesophageal conjunction adenocarcinoma: a prospective, multicenter phase II trial
by: Jinglei Qu, et al.
Published: (2023-04-01)

The apatinib and pemetrexed combination has antitumor and antiangiogenic effects against NSCLC
by: Zhou Ling, et al.
Published: (2023-03-01)

Activity and safety of apatinib monotherapy or apatinib combined with chemotherapy for patients with metastatic or unresectable osteosarcoma over the age of 40 years: A retrospective analysis
by: Taojun Gong, et al.
Published: (2022-11-01)

Pathological complete remission of a locally advanced gastric cancer by neoadjuvant therapy “sandwich” regimen as SOXAP+ fluorescence laparoscopic surgery +SOXAP: Case report
by: Yanling Ma, et al.
Published: (2022-11-01)

Efficacy and Safety of Apatinib in Treatment of Unresectable Intrahepatic Cholangiocarcinoma: An Observational Study
by: Hu Y, et al.
Published: (2020-07-01)

Research Progress of Combination Therapy of Apatinib on Tumor
by: WU Shan, et al.
Published: (2019-03-01)

Safety and efficacy of apatinib in patients with advanced gastric or gastroesophageal junction adenocarcinoma after the failure of two or more lines of chemotherapy (AHEAD): a prospective, single-arm, multicenter, phase IV study
by: Jin Li, et al.
Published: (2023-05-01)

The effect of apatinib combined with chemotherapy or targeted therapy on non‐small cell lung cancer in vitro and vivo
by: Mingtao Liu, et al.
Published: (2019-10-01)

Apatinib for recurrent/progressive glioblastoma multiforme: A salvage option
by: Hong-Hong Zhang, et al.
Published: (2022-08-01)

Efficacy of apatinib 250 mg combined with chemotherapy in patients with pretreated advanced breast cancer in a real-world setting
by: Ruyan Zhang, et al.
Published: (2023-06-01)